What Dologin Treats: Main Uses and Benefits

Dologin (Mefenamic Acid) is commonly used across conditions characterized by periods of heightened symptoms, which may involve temporary discomfort and functional strain. It is applied across domains where additional symptomatic support is needed.

This medication is indicated for the relief of mild to moderate acute pain and for the treatment of primary dysmenorrhea. It is commonly used to help with symptoms related to headaches, dental discomfort, muscle aches, and general back pain, and may be relevant for easing symptoms associated with rheumatoid arthritis or osteoarthritis.

The medication's role is commonly used to help ease the overall symptom burden. It may assist with supporting functional stability during difficult episodes. Dologin is applied when symptoms create noticeable functional strain, such as the throbbing pain of menstrual cramps or localized inflammation and fever (pyrexia). By helping to address these disruptive symptom patterns, the medication contributes to improved comfort during episodes of heightened discomfort.

---

Quick Fact: Symptomatic Support
Primary Focus: Management of symptoms related to physical discomfort, inflammation, and fever.
Key Use: Commonly used to help with primary dysmenorrhea (menstrual cramps).
Symptom Type: May be relevant for mild to moderate, acute, or episodic pain manifestations.

---

Regulatory References

1. NIH DailyMed drug label

Who can and cannot use Dologin? - Official Regulatory Information

Regulatory authorities define Dologin's (Mefenamic Acid) eligibility based on patient age, pre-existing health, and physiological status.

Eligibility Classification	Rule (Strictly Label-Based)
Allowed Population	Adults and adolescents 14 years of age and older (for capsule/tablet formulation) [Source 1.3].
Use Not Established	Children younger than 14 years of age (safety and efficacy for this formulation are not established) [Source 1.3].

Absolute Contraindications (Must Not Use)

Dologin is contraindicated and must not be used by patients with the following conditions, as stated in the regulatory label:

• A known history of hypersensitivity (such as asthma, urticaria, or allergic rhinitis) to mefenamic acid, aspirin, or any other NSAID [Source 1.4].
• Active GI ulceration or chronic inflammation of the upper or lower gastrointestinal tract [Source 1.5].
• Severe renal failure, severe hepatic failure, or severe heart failure [Source 2.1].
• Treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery [Source 1.5].

Restricted Use Populations

Use is contraindicated in the last trimester of pregnancy (at or after 30 weeks gestation) and not recommended for nursing mothers [Source 4.1, 4.4]. Use is also not recommended for women attempting to conceive or for elderly patients requiring prolonged therapy [Source 2.1, 1.2]. Pre-existing conditions like dehydration must be corrected prior to initiation of therapy [Source 1.2].

Interactions with other medicines and products

Pharmacodynamic Risk Reinforcement

Co-administration with several medicinal product categories can lead to pharmacodynamic reinforcement, officially increasing the risk of adverse outcomes. This includes Anticoagulants (such as Warfarin) and other Anti-platelet agents, where co-use enhances the risk of gastrointestinal (GI) bleeding. The same risk is documented for co-use with Selective Serotonin Reuptake Inhibitors (SSRIs) and Corticosteroids. Use with other systemic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including high-dose Aspirin, should be avoided for the same reason.

Pharmacokinetic and Exposure Modification

Mefenamic Acid can interfere with the elimination of certain co-administered drugs, increasing their plasma concentrations. This includes Lithium, where a reduction in renal clearance may lead to toxicity, and Methotrexate, where plasma levels can rise. Conversely, the co-ingestion of Magnesium Hydroxide antacids is officially documented to significantly increase the rate and extent of Mefenamic Acid absorption, a notable pharmacokinetic change. The drug is substantially metabolized by the CYP2C9 enzyme, and reduced clearance may occur in poor metabolizers.

Official Restrictions and Conditions

Formal restrictions include a prohibition against use for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Additionally, a timing-based rule requires Mefenamic Acid not be taken for 8–12 days following the administration of Mifepristone. Alcohol consumption and Tobacco use are noted as factors that formally enhance the risk of GI bleeding and peptic ulceration.

Dologin is a nitrogen-containing bisphosphonate analog that functions by binding selectively to hydroxyapatite mineral crystals at sites of active bone remodeling. Once internalized by active osteoclasts during the resorption process, its primary mechanism involves the inhibition of the key enzyme farnesyl pyrophosphate synthase (FPPS). This enzymatic inhibition directly disrupts the intracellular mevalonate pathway, which prevents the synthesis of crucial isoprenoid lipids (such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate).

The depletion of these lipids prevents the prenylation and subsequent activation of small regulatory GTPases (like Rac and Rho), which are essential for osteoclast cytoskeletal integrity and their ability to adhere to the bone surface. This mechanistic cascade leads to osteoclast inactivation and apoptosis, resulting in decreased osteoclast-mediated bone resorption. The cellular consequence is a reduction in bone remodeling markers, modulating the overall physiological process.

The administration of Dologin (Mefenamic Acid) involves specific parameters for short-term use. The medicine is an oral formulation, typically available as a 250 mg capsule or a 500 mg tablet, and is not indicated for other routes of administration.

Dosing Protocol and Frequency

Treatment begins with an initial dose of 500 mg followed by a maintenance dose of 250 mg taken every six hours (q6h) as needed. This approach is based on the principle of administering the lowest effective dose for the shortest possible duration to achieve the treatment goal.

Administration Conditions and Duration

A condition for use is that Dologin be taken with food or milk to ensure appropriate intake and minimize discomfort. The duration of therapy is time-limited: treatment for acute pain should not exceed seven days, while its use for primary dysmenorrhea is limited to a maximum of two to three days per cycle.

Population and Procedural Rules

Specific age constraints exist, as the medication is not indicated for use in patients under the age of 14 years. Furthermore, if a scheduled dose is missed, the procedure is not to double the dose but to continue with the established dosing schedule.

Research Evidence / Overview of Studies for Dologin (Mefenamic Acid)

Research Evidence for Primary Dysmenorrhea

The research base for Dologin (Mefenamic Acid), exploring outcomes related to painful menstruation (known as primary dysmenorrhea), is well-documented and includes many Randomized Controlled Trials (RCTs), comparative trials, and subsequent Systematic Reviews. Studies were conducted on adult and young women diagnosed with primary spasmodic dysmenorrhea, sometimes including those with excessive menstrual bleeding (menorrhagia). Researchers primarily examined patient-reported outcomes describing perceived discomfort, focusing on how symptoms change over defined time intervals.

Studies monitored outcomes related to physical discomfort during the menstrual cycle. Findings describe patterns observed in the studies related to pain intensity and measured change in pain. Research describes changes measured during the study period when Mefenamic Acid was compared against inactive substances (placebo) and other study comparators. The evidence contributes to understanding symptom patterns, particularly concerning the use of additional pain medication (rescue medication) during episodes of heightened symptom activity.

Research Evidence for Mild to Moderate Acute Pain

Research into the use of Mefenamic Acid for general mild to moderate acute pain consists primarily of single-dose Randomized Controlled Trials and subsequent Systematic Reviews and analyses. These studies explored short-term symptom changes, often involving populations experiencing acute pain, such as that following dental procedures or minor surgeries. The studies examined symptom intensity or variability and monitored patient-reported outcomes describing perceived discomfort.

In these short-term research scenarios, Mefenamic Acid was evaluated in settings with varying symptom burdens. Mefenamic Acid was associated with measured changes in pain intensity and measured change in pain compared to placebo in single-dose trials. The data from individual trials and reviews described the range of the measured change in pain observed over the initial 4 to 6 hours post-treatment.

Overview of Long-Term Studies and Follow-up

Research focusing on chronic use, maintenance data, or the durability of response over many months or years is generally not well-established. The majority of clinical trials are designed for short-term or episodic use—for acute pain, studies are very short (hours), and for dysmenorrhea, trials typically span only a few menstrual cycles. Long-term effects are not fully established, and the follow-up durations were limited in the primary research base.

Evidence Gaps and Research Uncertainty

Despite the well-documented evidence, certain limitations remain. Comparative evidence is lacking for specific head-to-head trials against all modern alternatives. Furthermore, the limited information for long-term outcomes and the small sample sizes in many subgroup analyses mean that certainty remains low for populations outside the main study demographic.

Common questions about Dologin (FAQ)

---

Q: What are the approved uses for Dologin?

Official regulatory documents indicate that Dologin (Mefenamic Acid) is approved for the relief of mild to moderate acute pain in patients 14 years and older. It is also specifically indicated for the treatment of primary dysmenorrhea, which is painful menstruation. Official documents describe that therapy duration is limited to a maximum of seven days.

---

Q: What is the typical duration of pain relief associated with Dologin?

Official product information reports that the elimination half-life of Mefenamic Acid typically approximates 2 hours in adults. This reported half-life describes the timeframe in which the body typically eliminates the active substance.

---

Q: Can Dologin cause stomach upset or nausea?

Yes, regulatory documents list common gastrointestinal side effects associated with Dologin (Mefenamic Acid). These commonly reported reactions include nausea and abdominal pain. Other reported issues include vomiting and general stomach discomfort.

---

Q: Does Dologin typically cause drowsiness or affect alertness?

According to the official product information, Dologin can cause side effects that affect the nervous system. Drowsiness (somnolence) and dizziness are documented reactions. Due to these potential effects, official information advises caution regarding activities that require full alertness, such as driving or operating heavy machinery.

---

Q: Does Dologin affect blood pressure levels?

Regulatory sources state that the use of NSAIDs like Dologin (Mefenamic Acid) may be associated with cardiovascular effects. This can include the new onset of high blood pressure (hypertension) or the worsening of pre-existing high blood pressure.

---

Q: Is Dologin generally contraindicated for people with a history of heart conditions?

Dologin is contraindicated (must not be used) in patients with severe heart failure and for pain management following certain surgical procedures involving the heart. Official warnings advise that it should be used with caution in patients with pre-existing heart failure or high blood pressure.

---

Q: Is Dologin intended for chronic pain or acute pain?

Official regulatory labels classify Dologin as a medication defined for the relief of mild to moderate acute pain. Its use is defined for short-term treatment only, with the maximum duration for acute pain relief described as seven days.

---

Q: How quickly does Dologin begin working? (Onset)

Pharmacokinetic data in official documents indicates that peak plasma levels of the active substance are generally reached within 2 to 4 hours after the medicine is taken orally. This timeframe represents when the maximum concentration of the drug is generally observed in the blood.

---

Q: Can Dologin be taken with a common multivitamin?

General regulatory sources do not typically identify an interaction between Dologin (Mefenamic Acid) and a common multivitamin. However, it is important to disclose all medications, including vitamins and herbal remedies, to a healthcare professional.

---

Q: Are there known interactions between Dologin and common over-the-counter pain relievers?

Regulatory documents describe that the co-use of Dologin with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which includes high-dose aspirin, is associated with an increased risk of serious adverse effects. The use of multiple NSAIDs is generally avoided for safety reasons.

---

Q: Does Dologin interact with supplements or herbal remedies?

It is generally advised in regulatory information that all substances, including vitamins and herbs, should be disclosed to a healthcare professional. Although specific interactions are not always listed, these substances may potentially alter the safety and effectiveness of the medication.

---

Q: What does official data say about Dologin and the ability to operate heavy machinery?

Since Mefenamic Acid is associated with side effects like dizziness and drowsiness, official safety information advises caution. These effects may impact a person's judgment and ability to safely operate heavy machinery or drive.

---

Q: What is the general timeline for a Dologin treatment course?

The treatment course for acute pain is explicitly time-limited, and regulatory documents state it should not exceed 7 days. For painful menstruation, the use is restricted to a maximum of 2 to 3 days per menstrual cycle.

---

Q: Can Dologin cause issues with sleep or insomnia?

Yes, regulatory documents report that issues affecting sleep are among the documented side effects. Insomnia (trouble sleeping) and dream abnormalities have been reported in the psychiatric and nervous system categories.

---

Q: Is it possible to stop Dologin use suddenly?

Official product information indicates that Mefenamic Acid provides relief from symptoms and inflammation only for as long as the patient continues to take it. This indicates that Mefenamic Acid is a treatment that addresses symptoms rather than the underlying cause of a condition.

---

Q: Is Dologin typically taken for a short period or long term?

Dologin is classified as a medication intended for short-term use only. Official regulatory labels prohibit its use for long-term or chronic conditions, and the maximum duration allowed for the treatment of acute pain is described as seven days.

---

Q: Is generic Dologin available?

Yes, the active substance, Mefenamic Acid, is available as a generic medicine in many regions. Generic formulations are regulated to be bioequivalent to the reference product.

---

Q: Is there any information about Dologin affecting kidney or liver function?

Regulatory information notes that Mefenamic Acid may cause borderline elevations in liver function tests. Furthermore, in susceptible patients, the use of NSAIDs can cause a dose-dependent reduction in a certain compound that may precipitate renal failure.

---

Q: Does the efficacy of Dologin vary depending on the patient's weight or metabolism?

Official product information notes that the drug is metabolized in the body by a specific enzyme. Regulatory information advises that the speed of this metabolism may vary in certain patient populations.

---

Q: What information is available regarding Dologin use during dental procedures?

Official therapeutic indications for Mefenamic Acid include its use as an analgesic for the symptomatic relief of pain. This specifically includes pain associated with dental issues and pain following post-operative procedures.

---

Q: Are there specific warnings about Dologin for individuals with a history of mental health conditions?

Side effects that fall under the psychiatric and nervous system categories have been reported in regulatory documents. These include anxiety, confusion, depression, and hallucinations.

The official labeling specifies strict conditions for storing Dologin (Mefenamic Acid) to ensure stability. The product must be stored at Controlled Room Temperature, defined as 25 C (77 F), with permitted short-term excursions up to 30 C (86 F).

Storage Protection	Requirement
Environment	Keep in a cool, dry, well-ventilated place.
Container	Keep the container tightly closed to protect the medicine from light and humidity, as the active substance is sensitive to these factors.

For safety, the medication must be stored out of the sight and reach of children.

Disposal must adhere to environmental protection rules: do not allow the unused product to enter drains or wastewater. Expired or unused Dologin should be disposed of at an approved waste disposal plant or via a local drug take-back program, following all federal, state, and local regulations.